Related Experiment Video
Updated: Apr 16, 2026
An In Vitro Approach to Photodynamic Therapy
Published on: August 17, 2018
Laser-assisted vs. conventional daylight photodynamic therapies for actinic keratosis: a two-year randomized
Vivian Lindholm1, Mari Salmivuori1, Sonja Hahtola1
1Department of Dermatology, Allergology and Venereology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Background:
Actinic field cancerization is considered a chronic and relapsing condition. Thus, long-term clearance and prevention of cutaneous squamous cell carcinoma should be the fundamental goal of treatment.
Objectives:
This trial aims to compare long-term outcomes of two novel field treatments for actinic keratoses.
Methods:
The investigator-initiated intraindividual randomised controlled and evaluator-blinded trial compared fractional laser-assisted artificial- or natural daylight photodynamic therapy to daylight photodynamic therapy alone, as a split-head comparison of 60 patients with ≥ two actinic keratoses of the head, on a two-year follow-up.
Results:
The intention-to-treat analysis showed a significantly higher lesion-specific two-year sustained clearance with the laser-assisted treatment (p=0.003, 56.3% (147/261)) vs. 43.0% (108/251) for daylight photodynamic therapy alone. Additionally, 45.6% (26/57) of patients achieved two-year sustained partial clearance in the laser-assisted treatment compared to 31.6% (18/57) in daylight photodynamic therapy alone (p=0.064). Correspondingly, 15.8% (9/57) compared to 7.0% (4/57) of patients achieved sustained complete clearance (p=0.070). No squamous cell carcinomas developed on the treatment field, and in total three Bowen's diseases.
Conclusions:
Laser-assisted daylight photodynamic therapy seems to achieve a higher long-term sustained clearance and may be superior also on long-term compared to daylight photodynamic therapy alone in the treatment of actinic keratosis of all grades.
